fda semaglutide compounding warning november 2025 for weight loss | Blog FDA and Novo Nordisk Warned

The combination of post-cholecystectomy digestive changes and GLP-1-related gastrointestinal effects necessitates particular attention to your eating patterns

These medications are approved only for type 2 diabetes management and chronic weight management, and any use for RA would be considered off-label without supporting clinical evidence

A coworker had been using Semaglutide and mentioned research peptides during a coffee break

Grawert wasnt involved in the study

Semaglutide was removed from the FDA's drug shortage list in February 2025, and tirzepatide followed in December 2024

Many over-the-counter vitamins aren't absorbed well, especially in people with high BMI